keyword
https://read.qxmd.com/read/38702787/characterizing-oxphos-inhibitor-mediated-alleviation-of-hypoxia-using-high-throughput-live-cell-imaging
#1
JOURNAL ARTICLE
Anne P M Beerkens, Daan F Boreel, James A Nathan, Jiri Neuzil, Gang Cheng, Balaraman Kalyanaraman, Micael Hardy, Gosse J Adema, Sandra Heskamp, Paul N Span, Johan Bussink
BACKGROUND: Hypoxia is a common feature of many solid tumors and causes radiotherapy and immunotherapy resistance. Pharmacological inhibition of oxidative phosphorylation (OXPHOS) has emerged as a therapeutic strategy to reduce hypoxia. However, the OXPHOS inhibitors tested in clinical trials caused only moderate responses in hypoxia alleviation or trials were terminated due to dose-limiting toxicities. To improve the therapeutic benefit, FDA approved OXPHOS inhibitors (e.g. atovaquone) were conjugated to triphenylphosphonium (TPP+ ) to preferentially target cancer cell's mitochondria...
May 3, 2024: Cancer & Metabolism
https://read.qxmd.com/read/38699975/pegylated-interferon-alpha-peg-ifn%C3%AE-induced-interstitial-lung-disease-in-a-patient-with-chronic-hepatitis-b-a%C3%A2-case-report-and-literature-review
#2
JOURNAL ARTICLE
Minghui Shi, Shiyao Wang, Yanhong Ren, Ling Zhao, Min Liu, Lulu Yang, Ting Yang
OBJECTIVES: Interferon (IFN)-induced lung injury is a rare but severe complication. Studies are needed to elucidate the demographic characteristics, clinical manifestations, and prognostic features of IFN-induced interstitial lung disease (ILD). CASE REPORT: We report a patient with chronic hepatitis who developed ILD after interferon monotherapy. To further clarify the clinical characteristics of such patients, we searched for cases in which lung injury was documented as a side effect of hepatitis treatment and systematically analyzed all case reports for clinical manifestations, type of treatment, and outcomes...
May 3, 2024: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/38697425/rationalization-design-soluble-expression-and-peg-modification-of-highly-active-recombinant-human-porcine-uricase-mutant-protein
#3
JOURNAL ARTICLE
Mingjie Tong, Shengli Wang, Junxi Luan, Qiuling Xie, Luquan Wang, Xiaoyang Shen, Sheng Xiong
Uric acid is the end product of purine metabolism in humans due to inactivation of the uricase determined by the mutated uricase gene. Uricase catalyzes the conversion of uric acid into water-soluble allantoin that is easily excreted by the kidneys. Hyperuricemia occurs when the serum concentration of uric acid exceeds its solubility (7 mg/dl). However, modifications to improve the uricase activity is under development for treating the hyperuricemia. Here we designed 7 types of human-porcine chimeric uricase by multiple sequence comparisons and targeted mutagenesis...
April 30, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38695839/a-facile-and-scalable-method-to-synthesize-pegylated-pdmaema-for-gene-delivery
#4
JOURNAL ARTICLE
Jie Dou, Shupei Yu, Yuanwei Zhang
In recent years, cationic polymer vectors have been viewed as a promising method for delivering nucleic acids. With the advancement of synthetic polymer chemistry, we can control chemical structures and properties to enhance the efficacy of gene delivery. Herein, a facile, cost-effective, and scalable method was developed to synthesize PEGylated PDMAEMA polymers (PEO-PDMAEMA-PEO), where PEGylation could enable prolonged polyplexes circulation time in the blood stream. Two polymers of different molecular weights were synthesized, and polymer/eGFP polyplexes were prepared and characterized...
May 2, 2024: Biopolymers
https://read.qxmd.com/read/38694233/pegvaliase-for-the-treatment-of-phenylketonuria-final-results-of-a-long-term-phase-3-clinical-trial-program
#5
JOURNAL ARTICLE
Cary O Harding, Nicola Longo, Hope Northrup, Stephanie Sacharow, Rani Singh, Janet A Thomas, Jerry Vockley, Roberto T Zori, Kaleigh Bulloch Whitehall, Joshua Lilienstein, Kristin Lindstrom, Drew G Levy, Shaun Jones, Barbara K Burton
Phenylketonuria (PKU) is a genetic disorder caused by deficiency of the enzyme phenylalanine hydroxylase (PAH), which results in phenylalanine (Phe) accumulation in the blood and brain, and requires lifelong treatment to keep blood Phe in a safe range. Pegvaliase is an enzyme-substitution therapy approved for individuals with PKU and uncontrolled blood Phe concentrations (>600 μmol/L) despite prior management. Aggregated results from the PRISM clinical trials demonstrated substantial and sustained reductions in blood Phe with a manageable safety profile, but also noted individual variation in time to and dose needed for a first response...
June 2024: Molecular Genetics and Metabolism Reports
https://read.qxmd.com/read/38690778/elimination-study-of-intact-lipid-nanocapsules-after-intravenous-rat-administration
#6
JOURNAL ARTICLE
Vincent Lebreton, Samuel Legeay, Clara Rapenne, Patrick Saulnier, Frédéric Lagarce
Aim: The present study investigated renal elimination after intravenous administration of four different formulations of lipid nanocapsules (LNCs) containing dyes adapted to Förster resonance energy transfer (FRET-LNCs). Materials & methods: FRET-LNCs of 85 or 50 nm with or without a pegylated surface were injected and collected in the blood or urine of rats at different time points. Quantitative analysis was performed to measure intact FRET-LNCs. Results & conclusion: No intact LNCs were found in urine (0 particles/ml) for all formulations...
May 1, 2024: Nanomedicine
https://read.qxmd.com/read/38688662/pegylated-liposomal-doxorubicin-combined-with-trabectedin-as-a-treatment-option-in-uterine-sarcomas-a-single-institution-retrospective-analysis
#7
JOURNAL ARTICLE
Magdalena Steinlechner, Laura Strobel, Katharina Leitner, Teresa L Pan, Barin Feroz, Christian Marth, Alain G Zeimet
OBJECTIVE: The use of conventional doxorubicin in combination with trabectedin leads to a considerable prolongation of progression-free survival in the treatment of uterine sarcomas but is associated with dose-limiting toxicities. Significant progression-free survival improvement was recently obtained through treatment prolongation with trabectedin single agent. We hypothesize that the therapeutic index of pegylated liposomal doxorubicin combined with trabectedin could be superior to the combination with conventional doxorubicin due to a more favorable toxicity profile...
April 30, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38687026/polymeric-nanozyme-with-sod-activity-capable-of-inhibiting-self-and-metal-induced-%C3%AE-synuclein-aggregation
#8
JOURNAL ARTICLE
Álvaro Martínez-Camarena, Francesco Bellia, M Paz Clares, Graziella Vecchio, Julien Nicolas, Enrique García-España
Despite decades of research, Parkinson's disease is still an idiopathic pathology for which no cure has yet been found. This is partly explained by the multifactorial character of most neurodegenerative syndromes, whose generation involves multiple pathogenic factors. Two of the most important ones are the aggregation of α-synuclein and oxidative stress. In this work, we address both issues by synthesizing a multifunctional nanozyme based on grafting a pyridinophane ligand that can strongly coordinate CuII, onto biodegradable PEGylated polyester nanoparticles...
April 30, 2024: Chemistry: a European Journal
https://read.qxmd.com/read/38686453/stable-snow-lantern-like-aggregates-of-silicon-nanoparticles-suitable-as-a-drug-delivery-platform
#9
JOURNAL ARTICLE
Hennie Marie Johnsen, Seyedmehdi Hossaini Nasr, Ricardo De Luna, Werner Filtvedt, Michael J Sailor, Jo Klaveness, Marianne Hiorth
Nanomedicine is a growing field where development of novel organic and inorganic materials is essential to meet the complex requirements for drug delivery. This includes biocompatibility, suitability for surface modifications, biodegradability, and stability sufficient to carry a drug payload through various tissues for the desired timespan. Porous silicon nanoparticles (pSi NP) are shown to have several beneficial traits in drug delivery in addition to a porous structure to maximize drug loading. The conventional synthesis of pSi NP using electrochemical etching is costly, time-consuming and requires large quantities of highly toxic hydrofluoric acid (HF)...
April 30, 2024: Nanoscale
https://read.qxmd.com/read/38685882/dimethyl-sulfoxide-as-a-gas-phase-charge-reducing-agent-for-the-determination-of-pegylated-proteins-intact-mass
#10
JOURNAL ARTICLE
Øystein Skjærvø, Alyssa Togle, Haley Sutton, Xuemei Han, Navin Rauniyar
Determination of PEGylated proteins' intact mass by mass spectrometry is challenging due to the molecules' large size, excessive charges, and instrument limitations. Previous efforts have been reported. However, signal variability, ion coalescence, and a generally low degree of robustness have been observed. In this work, we have explored the capabilities of post-column infusion of dimethyl sulfoxide (DMSO) following reversed-phase liquid chromatography-mass spectrometry (RP-LCMS) to determine PEG-filgrastim' intact mass, and to characterize its PEG moiety...
April 30, 2024: Analytical Methods: Advancing Methods and Applications
https://read.qxmd.com/read/38685810/exploring-the-antitumor-efficacy-of-pegylated-liposomes-loaded-with-licorice-extract-for-cancer-therapy
#11
JOURNAL ARTICLE
Zeinab Azizi Haghighat, Aliakbar Safekordi, Mehdi Ardjmand, Azim Akbarzadeh
BACKGROUND: Glycyrrhizic Acid (GA), a compound derived from licorice, has exhibited promising anticancer properties against several cancer types, including Prostate Cancer (PCa) and Gastric Cancer (GCa). OBJECTIVE: This study has introduced a novel approach involving the encapsulation of GA and Licorice extract (Lic) into Polyethylene Glycol Liposomes (PEG-Lip) and assessed their efficacy against AGS (human gastric cancer) and PC-3 (human prostate cancer) cells, marking the first report of this endeavor...
April 29, 2024: Current Cancer Drug Targets
https://read.qxmd.com/read/38685387/metal-coordination-nanotheranostics-mediated-by-nucleoside-metabolic-inhibitors-potentiate-sting-pathway-activation-for-cancer-metalloimmunotherapy
#12
JOURNAL ARTICLE
Lianyi Yang, Yazhen Wang, Yujun Song, Zeya Li, Lei Lei, Hanmei Li, Bin He, Jun Cao, Huile Gao
Activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is an effective way to initiate an immune response against tumors, and the research on agonists targeting STING has become a new hotspot in the development of antitumor drugs. However, as a novel STING agonist, the limited bioavailability and activation routes of manganese ions (Mn2+ ) significantly hinder its antitumor effects. To address these challenges, we have designed a metal-coordinated nucleoside metabolic inhibitor (gemcitabine, Gem)-induced metal nanotheranostic (MGP) with PEGylation...
April 27, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38684189/thrombin-generation-profile-using-st-genesia-after-peg-asparaginase-in-pediatric-patients-with-acute-lymphoblastic-leukemia
#13
JOURNAL ARTICLE
Anna Ruiz-Llobet, Susanna Gassiot, Edurne Sarrate, Josune Zubicaray, Susana Rives, Warda Suleman, Ruben Berrueco
BACKGROUND: Venous thromboembolism (VTE) etiology in children with acute lymphoblastic leukemia (ALL) is multifactorial. The use of global assays of hemostasis as thrombin generation test (TGT) is useful to individualize VTE risk in adult patients. The aim of this prospective cohort study was to evaluate the usefulness of an automated TGT to evaluate VTE risk during ALL treatment in children. METHODS: TGT (automated analyzer ST Genesia; ThromboScreen) and pro and anticoagulant plasma proteins were analyzed during ALL treatment in pediatric patients following LAL-SEHOP-PETHEMA-2013 guidelines...
April 29, 2024: Thrombosis and Haemostasis
https://read.qxmd.com/read/38683191/hepatitis-b-delta-assessment-of-the-knowledge-and-practices-of-hepato-gastroenterologists-practicing-in-non-academic-settings-in-france
#14
JOURNAL ARTICLE
Jean-François D Cadranel, Honoré T Zougmoré, Jean-René Ngele Efole, Bertrand Hanslik, Xavier Causse, Isabelle Rosa, Caroline Lemaitre, Camélia Mokhtari, Aurore Baron, Thierry Thevenot, Mourad Medmoun, Ryad Smadhi, Gildas Fantognon, André J Remy, Gilles Macaigne, Yves Arondel, Jean-Pierre Arpurt, Guy Bellaiche, Marc Bourlière, Caroline De Kerguenec, Frédéric Heluwaert, Juliette Verlynde, Philippe Halfon, Dominique Roulot, Paul Carrier, Véronique Loustaud-Ratti, Tristan Lemagoarou
BACKGROUND: Data on the management of Hepatitis B-Delta (HB-D) by hepatogastroenterologists (HGs) practicing in nonacademic hospitals or private practices are unknown in France. OBJECTIVE: We aimed to evaluate the knowledge and practices of HGs practicing in nonacademic settings regarding HB-D. METHODS: A Google form document was sent to those HGs from May to September 2021. RESULTS: A total of 130 HGs (mean age, 45 years) have participated in this survey...
June 1, 2024: European Journal of Gastroenterology & Hepatology
https://read.qxmd.com/read/38680424/pegunigalsidase-alfa-a-novel-pegylated-recombinant-alpha-galactosidase-enzyme-for-the-treatment-of-fabry-disease
#15
REVIEW
Dominique P Germain, Ales Linhart
Fabry disease, a rare X-linked genetic disorder, results from pathogenic variants in GLA , leading to deficient lysosomal α-galactosidase A enzyme activity and multi-organ manifestations. Since 2001, enzyme replacement therapy (ERT), using agalsidase alfa or agalsidase beta, has been the mainstay treatment, albeit with limitations such as rapid clearance and immunogenicity. Pegunigalsidase alfa, a novel PEGylated recombinant alpha-galactosidase, offers promise as an alternative. Produced in plant cells, pegunigalsidase alfa exhibits enhanced stability, prolonged half-life, and reduced immunogenicity due to pegylation...
2024: Frontiers in Genetics
https://read.qxmd.com/read/38680100/synthesis-of-pegylated-amphiphilic-block-copolymers-with-pendant-linoleic-moieties-by-combining-ring-opening-polymerization-and-click-chemistry
#16
JOURNAL ARTICLE
Julian D Porras, Ivonne L Diaz, Leon D Perez
This study focused on synthesizing and characterizing PEGylated amphiphilic block copolymers with pendant linoleic acid (Lin) moieties as an alternative to enhance their potential in drug delivery applications. The synthesis involved a two-step process, starting with ring-opening polymerization of ε-caprolactone (CL) and propargylated cyclic carbonate (MCP) to obtain PEG-b-P(CL-co-MCP) copolymers, which were subsequently modified via click chemistry. Various reaction conditions were explored to improve the yield and efficiency of the click chemistry step...
April 29, 2024: Biopolymers
https://read.qxmd.com/read/38679747/thrombopoietin-mimetic-stimulates-bone-marrow-vascular-and-stromal-niches-to-mitigate-acute-radiation-syndrome
#17
JOURNAL ARTICLE
Justin Vercellino, Beata Małachowska, Shilpa Kulkarni, Brett I Bell, Shahin Shajahan, Kosaku Shinoda, Gary Eichenbaum, Amit K Verma, Sanchita P Ghosh, Weng-Lang Yang, Paul S Frenette, Chandan Guha
BACKGROUND: Acute radiation syndrome (ARS) manifests after exposure to high doses of radiation in the instances of radiologic accidents or incidents. Facilitating regeneration of the bone marrow (BM), namely the hematopoietic stem and progenitor cells (HSPCs), is key in mitigating ARS and multi-organ failure. JNJ-26366821, a PEGylated thrombopoietin mimetic (TPOm) peptide, has been shown as an effective medical countermeasure (MCM) to treat hematopoietic-ARS (H-ARS) in mice. However, the activity of TPOm on regulating BM vascular and stromal niches to support HSPC regeneration has yet to be elucidated...
April 29, 2024: Stem Cell Research & Therapy
https://read.qxmd.com/read/38679244/plga-based-nanocarrier-for-combined-delivery-of-colchicine-and-purpurin-18-in-cancer-therapy-multimodal-approach-employing-cancer-cell-spheroids
#18
JOURNAL ARTICLE
Alma Lucia Villela Zumaya, Vladimíra Svobodová Pavlíčková, Silvie Rimpelová, Markéta Štějdířová, Michal Fulem, Ivana Křížová, Pavel Ulbrich, Pavel Řezanka, Fatima Hassouna
Improving the anticancer efficacy of chemotherapeutic drugs and photosensitizers requires innovative multifunctional nanoplatforms. This study introduces a chemo- and phototherapeutic drug delivery system (DDS) based on poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs), both PEGylated and non-PEGylated, with a mean size of 200 ± 75nm. Colchicine (Colch) and purpurin18 (P18) were co-encapsulated into these NPs, and their in vitro drug release profiles were investigated. The anticancer potential of these systems was evaluated across various cell lines (i...
April 26, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38677154/high-throughput-microfluidics-based-synthesis-of-pegylated-liposomes-for-precise-size-control-and-efficient-drug-encapsulation
#19
JOURNAL ARTICLE
Shima Akar, Somayeh Fardindoost, Mina Hoorfar
The low scalability and reproducibility of existing synthesis methods have hindered the translation of liposome nanoparticles as carriers for targeted drug delivery from conventional laboratory techniques to mass production. To this end, in this study, we present a high-throughput microfluidics-based approach for the synthesis of PEGylated liposomes with a primary focus on achieving precise size control and efficient encapsulation of hydrophobic drug molecules. In this platform, liposomes were self-assembled through a controllable mixing of lipids (EYPC, cholesterol, and DSPE-PEG 2000) dissolved in ethanol and an aqueous solution...
April 22, 2024: Colloids and Surfaces. B, Biointerfaces
https://read.qxmd.com/read/38676811/treatment-with-elapegademase-restores-immunity-in-infants-with-adenosine-deaminase-deficient-severe-combined-immunodeficiency
#20
JOURNAL ARTICLE
Elizabeth Daly Hicks, Geoffrey Hall, Michael S Hershfield, Teresa K Tarrant, Pawan Bali, John W Sleasman, Rebecca H Buckley, Talal Mousallem
PURPOSE: Patients with adenosine deaminase 1 deficient severe combined immunodeficiency (ADA-SCID) are initially treated with enzyme replacement therapy (ERT) with polyethylene glycol-modified (PEGylated) ADA while awaiting definitive treatment with hematopoietic stem cell transplant (HSCT) or gene therapy. Beginning in 1990, ERT was performed with PEGylated bovine intestinal ADA (ADAGEN®). In 2019, a PEGylated recombinant bovine ADA (Revcovi®) replaced ADAGEN following studies in older patients previously treated with ADAGEN for many years...
April 27, 2024: Journal of Clinical Immunology
keyword
keyword
41100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.